[go: up one dir, main page]

AR039336A1 - Sistemas analgesicos transdermicos con potencial de abuso reducido - Google Patents

Sistemas analgesicos transdermicos con potencial de abuso reducido

Info

Publication number
AR039336A1
AR039336A1 ARP030101384A ARP030101384A AR039336A1 AR 039336 A1 AR039336 A1 AR 039336A1 AR P030101384 A ARP030101384 A AR P030101384A AR P030101384 A ARP030101384 A AR P030101384A AR 039336 A1 AR039336 A1 AR 039336A1
Authority
AR
Argentina
Prior art keywords
analgesic
antagonist
reservoir
barrier layer
group
Prior art date
Application number
ARP030101384A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR039336A1 publication Critical patent/AR039336A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un sistema transdérmico para administrar un analgésico a través de la piel, sistema que tiene un potencial de abuso reducido, y comprende: (a) un reservorio para el analgésico que comprende un analgésico, analgésico que es seleccionado entre el grupo que consiste en fentanil y análogos del mismo; (b) un reservorio para el antagonista que comprende un antagonista para dicho analgésico; (c) una capa de barrera, capa de barrera que separa a dicho reservorio del antagonista de dicho reservorio del analgésico, capa de barrera que es sustancialmente impermeable a dicho analgésico y a dicho antagonista, donde el sistema (i) impide sustancialmente la liberación del antagonista del sistema una vez asegurado el sistema a un paciente humano durante un período de hasta 7 días y (ii) produce la liberación del antagonista a una velocidad suficiente para producir una relación de velocidad de liberación limitante del abuso del antagonista al analgésico cuando la forma de dosificación es objeto de abuso.. Reivindicación 27: El sistema de acuerdo con cualquiera de las reivindicaciones anteriores, en el cual el analgésico es un análogo del fentanil y el análogo es seleccionado entre el grupo que consiste en alfentanil, lofentanil, remifentanil, sufentanil y trefentanil y el antagonista es seleccionado entre el grupo que consiste en naltrexona, metilnaltrexona, naloxona, nalbufina, nalorfina, nalorfina dinicotinato, nalmefeno, nadida, levalorfan, ciclozocina y las sales farmacéuticamente aceptables de los mismos.
ARP030101384A 2002-04-23 2003-04-22 Sistemas analgesicos transdermicos con potencial de abuso reducido AR039336A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37511002P 2002-04-23 2002-04-23

Publications (1)

Publication Number Publication Date
AR039336A1 true AR039336A1 (es) 2005-02-16

Family

ID=29270594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101384A AR039336A1 (es) 2002-04-23 2003-04-22 Sistemas analgesicos transdermicos con potencial de abuso reducido

Country Status (20)

Country Link
US (2) US8440220B2 (es)
EP (1) EP1513507B1 (es)
JP (2) JP2005526839A (es)
KR (1) KR20050050615A (es)
CN (2) CN101406703A (es)
AR (1) AR039336A1 (es)
AT (1) ATE501712T1 (es)
AU (2) AU2003221752A1 (es)
CA (1) CA2496454A1 (es)
DE (1) DE60336394D1 (es)
ES (1) ES2361068T3 (es)
IL (1) IL164760A0 (es)
MX (1) MXPA04010612A (es)
NO (1) NO20045034L (es)
NZ (1) NZ535971A (es)
PE (1) PE20031016A1 (es)
TW (1) TW200404581A (es)
UY (1) UY27773A1 (es)
WO (1) WO2003090729A1 (es)
ZA (1) ZA200409396B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
NZ528148A (en) * 2001-03-16 2006-02-24 Alza Corp Transdermal patch for administering fentanyl
ATE501712T1 (de) * 2002-04-23 2011-04-15 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
WO2004026283A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
PE20081297A1 (es) * 2003-04-30 2008-09-17 Purdue Pharma Lp Forma de dosificacion transdermica resistente a la manipulacion
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
JP2007527415A (ja) * 2003-10-30 2007-09-27 アルザ・コーポレーシヨン 乱用の可能性が低い経皮鎮痛剤システム
US8535711B2 (en) * 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
PL1718258T3 (pl) * 2004-02-23 2009-08-31 Euro Celtique Sa Odporne na nadużywanie transdermalne urządzenie do podawania opioidu
US20050202073A1 (en) * 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) * 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
KR20070053267A (ko) * 2004-08-20 2007-05-23 쓰리엠 이노베이티브 프로퍼티즈 컴파니 반투명 보호 필름을 갖는 경피 약물 전달 장치
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc BIOSYNCHRONE TRANSDERMAL MEDICINES
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
ATE471146T1 (de) 2004-10-21 2010-07-15 Durect Corp Transdermale verabreichungssysteme
US7827983B2 (en) * 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
WO2006073170A1 (ja) 2005-01-07 2006-07-13 Universal Bio Research Co., Ltd. 担体封入チップ、担体処理装置、および担体処理方法
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
EP1895994B1 (en) 2005-05-13 2010-08-25 ALZA Corporation Multilayer drug delivery system with barrier against reservoir material flow
WO2006124749A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against antagonist exposure
CN101009530B (zh) * 2006-01-23 2012-02-15 华为技术有限公司 支持组播类业务的无源光网络、复用/解复用器及方法
KR20140079441A (ko) * 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
CN101902996B (zh) * 2007-10-15 2014-11-26 阿尔扎公司 芬太尼的一天更换一次透皮施用
US8165669B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8195287B2 (en) * 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US20090149797A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System for reversible chemical modulation of neural activity
US8180446B2 (en) * 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8233976B2 (en) 2007-12-05 2012-07-31 The Invention Science Fund I, Llc System for transdermal chemical modulation of neural activity
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8165668B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8170659B2 (en) * 2007-12-05 2012-05-01 The Invention Science Fund I, Llc Method for thermal modulation of neural activity
US8160695B2 (en) * 2007-12-05 2012-04-17 The Invention Science Fund I, Llc System for chemical modulation of neural activity
AU2008338442A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US9700552B2 (en) * 2008-02-28 2017-07-11 Syntropharma Limited Pharmaceutical compositions for treatment of addiction
WO2009120889A2 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
CN101434708B (zh) * 2008-12-19 2012-01-11 成都中科来方能源科技有限公司 水性聚合物改性微孔聚烯烃隔膜及其制备方法和用途
ES2660674T3 (es) 2009-03-04 2018-03-23 Emplicure Ab Formulación resistente al abuso
JP5691051B2 (ja) 2009-05-08 2015-04-01 エンプリキュア・アクチエボラゲット ジオポリマー結合剤を含む持続薬物送達用組成物
DE102009036485B4 (de) * 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
EP3064199B1 (en) * 2010-04-02 2023-12-20 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
DK2557924T3 (da) 2010-04-13 2019-09-23 Relmada Therapeutics Inc Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse
DK2613784T3 (da) 2010-09-07 2018-01-29 Emplicure Ab Indretning til transdermal indgivelse af lægemiddel
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
RU2014108664A (ru) 2011-09-30 2015-11-10 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Общая система утилизации лекарственных средств
JP5964435B2 (ja) 2011-09-30 2016-08-03 テイコク ファーマ ユーエスエー インコーポレーテッド 経皮パッチ廃棄システム
EP3096746B1 (en) 2014-01-22 2019-03-13 4P Therapeutics Abuse and misuse deterrent transdermal systems
US11607026B2 (en) 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
EP3169318B1 (en) 2014-07-18 2020-04-01 Buzzz Pharmaceuticals Limited Abuse deterrent opiod/opiod-antagonist transdermal patch
US9623017B2 (en) 2014-09-24 2017-04-18 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
JP2018511127A (ja) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 渇望入力及び支援システム
WO2017053936A1 (en) 2015-09-24 2017-03-30 Pain Therapeutic, Inc. Cocrystals of naloxone and naltrexone
GB201600919D0 (en) * 2016-01-18 2016-03-02 Buzzz Pharmaceuticals Ltd Transdermal patch
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
EP4684865A2 (en) 2017-04-18 2026-01-28 Nouvel Technologies Inc. Sulfur production
KR20210008328A (ko) 2018-03-07 2021-01-21 수부 랩스, 인크. 열 섬유의 자극을 통한 통증 완화 개선을 위한 시스템 및 방법
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020008370A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
DE102018216244A1 (de) * 2018-09-24 2020-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Barriereschicht
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
JP6912122B2 (ja) * 2019-02-28 2021-07-28 日本臓器製薬株式会社 経皮投与製剤
CN112810171B (zh) * 2021-01-22 2025-10-31 东莞市高贝瑞自动化科技有限公司 一种耳机套全自动生产线
WO2022249748A1 (ja) * 2021-05-24 2022-12-01 住友精化株式会社 ゲル状組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US5310559A (en) 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5186939A (en) 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5762952A (en) 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
AU6657396A (en) * 1995-07-28 1997-02-26 Novartis Ag Transdermal system
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
US5783583A (en) 1996-04-12 1998-07-21 Simon; David Lew 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification
TW411277B (en) 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998017315A2 (en) 1996-10-24 1998-04-30 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DE19653605C2 (de) 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
DE19653606A1 (de) 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
AU776904B2 (en) 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
NZ528148A (en) 2001-03-16 2006-02-24 Alza Corp Transdermal patch for administering fentanyl
EP2062573B1 (en) * 2001-05-01 2011-11-16 Euro-Celtique S.A. Abuse resistant opioid containing transdermal systems
ATE501712T1 (de) * 2002-04-23 2011-04-15 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
ATE423560T1 (de) * 2002-08-20 2009-03-15 Euro Celtique Sa Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
JP2007527415A (ja) * 2003-10-30 2007-09-27 アルザ・コーポレーシヨン 乱用の可能性が低い経皮鎮痛剤システム

Also Published As

Publication number Publication date
PE20031016A1 (es) 2003-11-29
UY27773A1 (es) 2003-09-30
JP2005526839A (ja) 2005-09-08
CN1720028A (zh) 2006-01-11
MXPA04010612A (es) 2005-07-14
NO20045034L (no) 2005-01-19
ATE501712T1 (de) 2011-04-15
IL164760A0 (en) 2005-12-18
JP5453211B2 (ja) 2014-03-26
TW200404581A (en) 2004-04-01
US8440220B2 (en) 2013-05-14
EP1513507B1 (en) 2011-03-16
CN101406703A (zh) 2009-04-15
NZ535971A (en) 2007-07-27
ES2361068T3 (es) 2011-06-13
DE60336394D1 (de) 2011-04-28
US8747889B2 (en) 2014-06-10
AU2009202407A1 (en) 2009-07-09
CA2496454A1 (en) 2003-11-06
JP2011057684A (ja) 2011-03-24
US20130251760A1 (en) 2013-09-26
US20040013716A1 (en) 2004-01-22
EP1513507A1 (en) 2005-03-16
KR20050050615A (ko) 2005-05-31
WO2003090729A1 (en) 2003-11-06
AU2003221752A1 (en) 2003-11-10
ZA200409396B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
AR039336A1 (es) Sistemas analgesicos transdermicos con potencial de abuso reducido
JP2744102B2 (ja) 乱用の可能性を減じた投与形
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
JP2009544619A5 (es)
SI1554282T1 (sl) Derivati morfinana, substituirani v legi 14 in njihove kvarternarne amonijeve soli, postopek izdelave in uporaba
HRP20191909T1 (hr) Novi i potentni oblici doze tapentadola
JP6279547B2 (ja) オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
ATE326222T1 (de) Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
JP2011137020A5 (es)
JP2011252020A (ja) 依存性退薬症状の治療
RU2007149044A (ru) Твердые лекарственные формы наркотических лекарственных средств с улучшенным всасыванием при трансбуккальном введении
CL2011000044A1 (es) Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
RU2016123972A (ru) Применение антагониста опиоидных рецепторов с к-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками
HRP20110049T1 (en) Opioids for the treatment of the restlessness of the lower limbs
EA200870182A1 (ru) Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
US20080226702A1 (en) Transdermal Delivery Form Disposal Systems and Methods
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
RU2012124063A (ru) Лекарственная комбинация с теобромином и ее использование в лечении
JP2013510842A5 (es)
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
JP2017526719A5 (es)
JP2017526719A (ja) オピオイド誘発性多幸症を減弱するためのシステム及び方法
AU2003230034A8 (en) Transdermal delivery device for the administration of fentanyl
KR20100052490A (ko) (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여

Legal Events

Date Code Title Description
FA Abandonment or withdrawal